[Changchun High-tech: Leuprorelin mesylate injection (6M) received drug registration certificate] On October 8, Changchun High-tech (000661.SZ) announced that the company's holding subsidiary Jinsai Pharmaceutical received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration. The overseas production drug registration and marketing license application for leuprolide mesylate injection (6M) was approved, and the approved indication is prostate cancer requiring androgen castration therapy. This product is a long-acting subcutaneous injection preparation with a dosing interval of 6 months, which can improve patients' medication compliance. This approval will help enrich the company's product layout in the oncology field and enhance market competitiveness.